• Hoechst 33342: Imaging Context and Evidence Boundaries

  2026-10-13

  Hoechst 33342 is a bis-benzimidazole fluorescent dye used conceptually for nuclear and chromatin visualization. The supplied GERD study provides preclinical evidence about berberine, evodiamine, TAS2R38, and TRPV1, but it does not establish a role for Hoechst 33342 or support clinical treatment claims.

• Hcp2b, Lysosomal Dysfunction and Autophagy

  2026-10-13

  A source-grounded overview of a 2026 study reporting that the APEC effector Hcp2b disrupts lysosomal function and stalls autophagic degradation in HD11 chicken macrophage-like cells, with attention to evidence strength, interpretation and applicability limits.

• Bradford Protein Assay Kit: Evidence and Scope

  2026-10-12

  The Bradford Protein Assay Kit (SKU K4103) is presented by APExBIO as a Coomassie dye-based biochemical protein assay for estimating protein concentration in solution. The supplied evidence consists of product information only; no matched independent paper is available to verify its performance claims or broader applicability.

• Psora 4 and the Context of Kv1.3 Pharmacology

  2026-10-12

  Psora 4 is a research small-molecule Kv1.3 blocker used to examine ion-channel control of leukocyte function. Recent peer-reviewed work indicates that the auxiliary subunit KCNE4 can change Psora 4 inhibition kinetics without materially changing apparent affinity, underscoring the limits of interpreting blocker selectivity from simplified channel systems alone.

• Drug Response Metrics in Cancer In Vitro

  2026-10-10

  Hannah Schwartz’s 2022 dissertation examines a central problem in cancer pharmacology: relative viability and fractional viability are often treated as interchangeable even though they capture different biological outcomes. Its key finding is that most tested drugs influence both proliferation and cell death, but with distinct magnitudes and timing, making assay interpretation more precise when growth inhibition and killing are evaluated separately.

• Puromycin Dihydrochloride: Evidence and Applications

  2026-10-09

  Puromycin dihydrochloride is an aminonucleoside antibiotic used conceptually to interrogate protein synthesis and selectable cell-line biology. This overview separates supplier-described properties from findings in a peer-reviewed NSCLC study and defines the limits of applying puromycin-related interpretations to TRAIL receptor and IL-8 research.

• Difloxacin HCl: An Evidence-Based Research Framework

  2026-10-09

  Difloxacin HCl supports research spanning bacterial DNA replication inhibition, antimicrobial susceptibility testing, and multidrug resistance reversal. This article distinguishes established product claims from mechanistic evidence and uses a mitotic checkpoint study to show how cross-domain interpretation can remain scientifically rigorous.

• (-)-Blebbistatin and Mechanomemory Logic

  2026-10-08

  Discover how (-)-Blebbistatin, a selective non-muscle myosin II inhibitor, can clarify whether mechanomemory depends on F-actin remodeling, actomyosin force transmission, or both. This evidence-led analysis connects the compound’s molecular action with YAP signaling while defining key interpretation limits.

• Sumatriptan’s Anti-Inflammatory Evidence: A Review

  2026-10-08

  Ala and colleagues’ systematic review examines whether sumatriptan has pharmacological effects beyond migraine relief, integrating evidence involving cytokines, nitric oxide signaling, caspases, and CGRP release. The review supports anti-inflammatory activity as a biologically plausible research hypothesis, while its heterogeneous, largely experimental evidence base does not establish sumatriptan as a broadly validated anti-inflammatory treatment.

• Autophagy–Liver Metastasis Signature in CRC

  2026-10-07

  Bai et al. integrated bulk and single-cell transcriptomic analyses to develop a six-gene prognostic signature connecting autophagy, liver metastasis, and immune dysfunction in colorectal cancer. The study supports risk stratification and hypothesis generation around immunotherapy resistance, while its retrospective design means prospective and functional validation remain necessary.

• KG-501 in CAC: Reading Mechanism Carefully

  2026-10-07

  KG-501 offers a focused lens for interpreting CREB–coactivator signaling in colitis-associated colorectal cancer research. This article examines how its mechanism intersects with the Liu et al. JXY study while separating pathway evidence from causal proof.

• UBR1 and UBR2 as ER Stress Sensors

  2026-10-06

  The reference study identifies the E3 ligases UBR1 and UBR2 as mammalian N-recognins that become more stable during endoplasmic reticulum stress and support cellular protein-quality control. Its findings expand ER-associated degradation beyond established membrane-associated ligases while showing that loss of UBR1 and UBR2 increases susceptibility to stress-linked apoptosis.

• TMRE and Mitochondrial Membrane Potential Research

  2026-10-06

  TMRE provides a fluorescence-based proxy for mitochondrial membrane potential, a useful but indirect measure of mitochondrial state. This overview places the Tetramethylrhodamine ethyl ester mitochondrial probe in the context of sodium-induced mitochondrial dysfunction and NECSO, emphasizing published findings, evidence strength, and interpretive limitations.

• GSK 2837808A and the Lactate–Immunity Frontier

  2026-10-05

  A translational perspective on GSK 2837808A as a research tool for connecting LDHA-dependent lactate metabolism with immune regulation, while separating established hepatocellular carcinoma evidence from exploratory colorectal cancer hypotheses.

• Difloxacin HCl: Evidence Across Two Research Axes

  2026-10-05

  Difloxacin HCl supports research spanning antimicrobial susceptibility testing and multidrug resistance reversal. This evidence-focused analysis separates its bacterial and transporter-related applications from the distinct mitotic checkpoint biology reported for Plk1 and p31comet.

8603 records 2/574 page Previous Next 12345 下5页 Last page